Noveze (Ezetimibe)

Ezetimibe, the active ingredient in Noveze, is a cholesterol absorption inhibitor presented as an oral tablet for oral use. It reduces elevated cholesterol levels by limiting intestinal absorption of dietary and biliary cholesterol, and is prescribed for patients with primary hyperlipidemia, familial hypercholesterolemia, or homozygous familial hypercholesterolemia who require additional lipid lowering.

GNH USA supplies Noveze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, traceability and regulatory compliance across all markets, through rigorous manufacturing standards and validated distribution processes.

Ezetimibe is used to lower cholesterol by targeting intestinal absorption pathways in several lipid disorders.

- Hypercholesterolemia: reduces LDL‑cholesterol levels when used alone or with statins. - Familial hypercholesterolemia: helps achieve target lipid levels in genetically predisposed patients. - Homozygous familial hypercholesterolemia: provides additional cholesterol reduction in severe cases. - Primary hyperlipidemia: lowers total cholesterol and LDL‑C as part of a comprehensive lipid‑lowering regimen.

Ezetimibe is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Abdominal pain: mild discomfort in the stomach area. - Diarrhea: loose stools occurring intermittently. - Fatigue: feeling unusually tired. - Headache: mild to moderate head pain. - Nausea: sensation of unease in the stomach.

Serious or Rare Side Effects: - Myopathy: muscle pain or weakness, potentially indicating muscle injury. - Elevated liver enzymes: signs of liver stress requiring monitoring. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Pancreatitis: severe abdominal pain possibly indicating pancreatic inflammation. - Severe hypersensitivity: anaphylactic symptoms requiring immediate medical attention.

Before initiating therapy, several precautions should be considered.

- Monitor lipid profile: assess efficacy and safety regularly. - Assess liver function: check hepatic enzymes prior to and during treatment. - Evaluate renal function: adjust use in patients with severe kidney impairment. - Avoid use in active gallbladder disease: may exacerbate biliary conditions. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Ezetimibe may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cyclosporine: can increase ezetimibe plasma concentrations. - Bile acid sequestrants: may bind ezetimibe and reduce its absorption if taken simultaneously. - Strong CYP3A4 inducers: can lower ezetimibe exposure and effectiveness.

Moderate Interactions (Monitor Closely): - Statins: combined use may raise the risk of myopathy. - Warfarin: ezetimibe may affect INR, requiring closer coagulation monitoring. - Fibrates: potential additive effect on liver enzymes, necessitating periodic liver function tests.